Drug intelligence / Profile preview

SHR175593

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

SHR175593 is the **active metabolite** of HRS4800, a drug candidate under investigation for pain management. SHR175593 is measured as the pharmacologically active entity in clinical trials assessing HRS4800 and is evaluated for safety, tolerability, and pharmacokinetic properties after oral administration of HRS4800 in healthy human subjects. The mechanism of action, molecular target, and detailed pharmacology of SHR175593 have not been explicitly disclosed in published sources, but it is a small molecule developed for its potential analgesic effects[1][3][5][7].

Beyond the preview

Go deeper on SHR175593.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR175593.

Explore the full profile